Cargando…

Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma

Understanding the metabolic reprogramming of aggressive brain tumors has potential applications for therapeutics as well as imaging biomarkers. However, little is known about the nutrient requirements of isocitrate dehydrogenase 1 (IDH1) mutant gliomas. The IDH1 mutation involves the acquisition of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-Rodado, Victor, Seki, Tomohiro, Dowdy, Tyrone, Lita, Adrian, Zhang, Meili, Han, Sue, Yang, Chunzhang, Cherukuri, Murali K., Gilbert, Mark R., Larion, Mioara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352932/ https://www.ncbi.nlm.nih.gov/pubmed/32575619 http://dx.doi.org/10.3390/cancers12061633

Ejemplares similares

Sphingolipid Pathway as a Source of Vulnerability in IDH1(mut) Glioma
por: Dowdy, Tyrone, et al.
Publicado: (2020)

DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021)

BIMG-10. IDH1 MUTATIONS INDUCE ORGANELLE DEFECTS VIA DYSREGULATED PHOSPHOLIPIDS
por: Yamasaki, Tomohiro, et al.
Publicado: (2021)

Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model
por: Ruiz-Rodado, Victor, et al.
Publicado: (2022)

Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
por: Ruiz-Rodado, Victor, et al.
Publicado: (2020)

CBMS-5 STEAROYL-COA DESATURASE INHIBITOR INDUCES APOPTOSIS VIA ENHANCING LIPOLYSIS IN IDH MUTANT GLIOMA
por: Zhang, Lumin, et al.
Publicado: (2022)

DDRE-16. CYSTEINE IS AN ESSENTIAL AMINO ACID IN GLIOMAS
por: Ruiz-Rodado, Victor, et al.
Publicado: (2021)

Cysteine is a limiting factor for glioma proliferation and survival
por: Ruiz‐Rodado, Victor, et al.
Publicado: (2022)

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
por: Han, Sue, et al.
Publicado: (2020)

IDH1 mutations induce organelle defects via dysregulated phospholipids
por: Lita, Adrian, et al.
Publicado: (2021)

DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021)

Targeting the Sphingolipid Rheostat in Gliomas
por: Zaibaq, Faris, et al.
Publicado: (2022)

Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy
por: Larion, Mioara, et al.
Publicado: (2018)

OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation
por: Mortazavi, Armin, et al.
Publicado: (2021)

Magnetic resonance spectroscopy for the study of cns malignancies
por: Ruiz-Rodado, Victor, et al.
Publicado: (2020)

DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
por: Lita, Adrian, et al.
Publicado: (2021)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/β-Catenin Signaling in IDH1-mutant Gliomas
por: Zhou, Yiqiang, et al.
Publicado: (2019)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
por: Dimitrov, Lilia, et al.
Publicado: (2015)

Altered metabolic landscape in IDH‐mutant gliomas affects phospholipid, energy, and oxidative stress pathways
por: Fack, Fred, et al.
Publicado: (2017)

mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma
por: Liu, Yang, et al.
Publicado: (2020)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Probabilistic model checking of cancer metabolism
por: Friedenberg, Meir D., et al.
Publicado: (2022)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma
por: Ren, L., et al.
Publicado: (2020)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_db2b3t0susvbt7h8i3ft5st1pf